GlassScriptPhysician profile
Jack W Finch
NPI 1629168091
$18,592.78
in general payments reported to CMS, 2019-2025
39 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $2,262 · 2021: $3,267 · 2022: $2,540 · 2023: $2,668 · 2024: $2,562 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,147.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,711.64 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,838.92 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,795.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,598.29 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $1,225.52 | 2019-2025 | |
| Novo Nordisk INC | $1,039.75 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $996.89 | 2020-2025 | Xifaxan, Trulance |
| Amgen INC. | $946.22 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $858.48 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $744.04 | 2019-2020 | |
| Eisai INC. | $451.86 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $446.24 | 2019-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $414.45 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $343.97 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $332.06 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Finch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.